Device-Free Auricular Acupressure for Rosacea: A Randomized Clinical Trial.

Authors

Bingyang Xu, Jiali Chu, Ye Wang, Yuanqin Wang, Liuyun Li, Yan Yang, Biao Yu, Tong Xiao, Peiwen Yang, Na Wu, Hong Sun, Shengxiang Xiao, Yumin Xia, Peng An, Tianxiao Zhang, Jiawen Wu

Published in

JAMA dermatology. Oct 14, 2026. Epub Oct 14, 2026.

Abstract

Transcutaneous auricular vagus nerve stimulation is effective for rosacea. However, its neuroimmunomodulatory effects lack sham-controlled serum biochemical evidence, and specialized device reliance limits its clinical popularization.
To evaluate the clinical efficacy of device-free auricular acupressure for rosacea and verify its neuroimmunomodulatory effects using serum biomarkers and immediate vascular imaging in a sham-controlled trial.
This single-center, randomized, sham-controlled, assessor-masked trial was conducted in the Dermatology Outpatient Department of the Second Affiliated Hospital of Xi'an Jiaotong University from October 2025 to May 2026 and included 204 patients with rosacea who were receiving standard first-line treatment. Participants were assigned in a 1:1 ratio using block randomization. Data analysis was initiated in May 2026.
The active acupressure group received a Vaccaria segetalis seed on the bilateral cavum conchae (innervated by the auricular vagus branch), while the sham group received a seed on the auricular tubercle superior margin (pure somatosensory innervation). Participants performed acupressure 3 times daily for 30 seconds, with extra pressing allowed during acute flare-ups. The intervention lasted 8 weeks. Serum levels of cathelicidin antimicrobial peptide (LL-37), calcitonin gene-related peptide (CGRP), tumor necrosis factor α (TNF-α), and interleukin (IL) 6 were measured at baseline and week 8. Multispectral imaging was performed at baseline and week 4 to assess immediate vascular responses.
The primary outcome was treatment success, defined as an Investigator Global Assessment (IGA) score of 0 or 1 at week 8. The number needed to treat was calculated from absolute risk difference.
The 204 participants were equally divided into 2 groups (102 each; active acupressure: mean [SD] age, 32.51 [10.60] years, 86 female individuals [84.3%]; sham acupressure: mean [SD] age, 30.82 [9.32] years, 86 female individuals [84.3%]). At week 8, the active acupressure group had a higher IGA success rate (58 [56.9%] vs 36 [35.3%]; relative risk, 1.61; 95% CI, 1.18-2.20; P = .003; number needed to treat, 5). Serum LL-37, CGRP, TNF-α, and IL-6 levels decreased more significantly in the active acupressure group. The immediate vascular improvement rate was 59.3% vs 7.4% (P < .001). At week 20, the active acupressure group maintained significantly lower IGA and Clinical Erythema Assessment scores. No serious adverse events occurred.
This randomized clinical trial found that device-free, on-demand intervention yielded substantial additional clinical benefits when combined with standard first-line therapy and established early sham-controlled, serum-based evidence for its neuroimmunomodulatory mechanism, potentially offering a strategy for self-management of rosacea.
Chinese Clinical Trial Registry Identifier: ChiCTR2500110787.

PMID:
42873508
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.